Mirzaei Hamed, Momeni Fatemeh, Saadatpour Leila, Sahebkar Amirhossein, Goodarzi Mohammad, Masoudifar Aria, Kouhpayeh Shirin, Salehi Hossein, Mirzaei Hamid Reza, Jaafari Mahmoud Reza
Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Cell Physiol. 2018 Feb;233(2):856-865. doi: 10.1002/jcp.25787. Epub 2017 Jun 22.
Stroke is a life-threatening disease that accounts for a considerable burden of mortality in both developing and developed world. Identification of specific biomarkers for stroke and its outcomes can greatly contribute to improved care of patients. MicroRNAs (miRNAs) are known as novel biomarkers that could be used as diagnostic, prognostic, and therapeutic biomarkers. Various studies have shown that miRNAs have key roles in the pathogenesis of stroke, and its complications and outcomes. In addition, there is evidence showing that mesenchaymal stromal cell-derived exosomes containing miRNAs can be used for monitoring and treatment of various diseases such as stroke. Here, we summarized various aspects of miRNA applications in different stages of stroke.
中风是一种危及生命的疾病,在发展中国家和发达国家都造成了相当大的死亡负担。识别中风及其预后的特定生物标志物有助于极大地改善患者的护理。微小RNA(miRNA)作为新型生物标志物,可用于诊断、预后评估和治疗。多项研究表明,miRNA在中风的发病机制、并发症及预后中发挥关键作用。此外,有证据表明,含有miRNA的间充质基质细胞衍生外泌体可用于监测和治疗中风等多种疾病。在此,我们总结了miRNA在中风不同阶段应用的各个方面。